Lauri A. Aaltonen
University of Helsinki
396 Papers
3.2K Citations
Lauri A. Aaltonen is an academic researcher from University of Helsinki. The author has contributed to research in topics: Germline mutation & Cancer. The author has an hindex of 103, co-authored 371 publications. Previous affiliations of Lauri A. Aaltonen include Harvard University & Karolinska Institutet.
Chat about Author
Papers
Better survival rates in patients with MLH1-associated hereditary colorectal cancer
TL;DR: MLH1-associated colorectal cancer has a natural history different from that of common sporadic coloreCTal cancer, and the better survival rates may be caused by the heavy mutation burden affecting mismatch repair deficient tumor cells.
BasePlayer: Versatile Analysis Software for Large-scale Genomic Variant Discovery
Riku Katainen,Iikki Donner,Tatiana Cajuso,Eevi Kaasinen,Kimmo Palin,Mäkinen,Lauri A. Aaltonen,Esa Pitkänen +7 more
TL;DR: A highly efficient and user-friendly software, BasePlayer, for biological discovery in large-scale NGS data, designed primarily for whole-genome and exome sequencing data, and well-suited to various study settings, diseases and organisms by supporting standard and upcoming file formats.
Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate
Åsa Kolterud,Niko Välimäki,Heli Kuisma,Joonatan Patomo,Sini T Ilves,Netta Mäkinen,Jaana Kaukomaa,Kimmo Palin,Eevi Kaasinen,Auli Karhu,Annukka Pasanen,Ralf Bützow,Oskari Heikinheimo,Helena Kopp Kallner,Lauri A. Aaltonen +14 more
TL;DR: The work provides a proof-of-principle that uterine fibroid treatment response is influenced by molecular subclass and that the genetic subclasses should be taken into account when evaluating current and future uterine Fibroid therapies.
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Akseli Hemminki,Akseli Hemminki,Jukka-Pekka Mecklin,Heikki Järvinen,Lauri A. Aaltonen,Heikki Joensuu +5 more
TL;DR: Adjuvant 5-FU-based chemotherapy is feasible for both microsatellite instability (MSI) and MSI(-) CRCs, and patients with MSI(+) CRC who receive adjuvant therapy have an excellent prognosis.
LKB1 somatic mutations in sporadic tumors.
Egle Avizienyte,Anu Loukola,Stina Roth,Akseli Hemminki,Maija Tarkkanen,Reijo Salovaara,Johanna Arola,Ralf Bützow,Kirsti Husgafvel-Pursiainen,Arto Kokkola,Heikki Järvinen,Lauri A. Aaltonen +11 more
TL;DR: The results suggest that mutational inactivation of LKB1 is a rare event in most sporadic tumor types.